ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Field of Research : Paediatrics
Research Topic : growth factor therapy
Clear All
Filter by Field of Research
Paediatrics (38)
Clinical Sciences (1)
Community Child Health (1)
Rehabilitation And Therapy: Hearing And Speech (1)
Filter by Socio-Economic Objective
"Occupational, speech and physiotherapy" (1)
Child health (1)
Hearing, vision, speech and their disorders (1)
Filter by Funding Provider
National Health and Medical Research Council (37)
Australian Research Council (1)
Filter by Status
Closed (38)
Filter by Scheme
NHMRC Project Grants (21)
Project Grants (8)
Early Career Fellowships (4)
Postgraduate Scholarships (2)
Discovery Projects (1)
NHMRC Development Grants (1)
NHMRC Postgraduate Scholarships (1)
Filter by Country
Australia (3)
Filter by Australian State/Territory
QLD (2)
VIC (2)
  • Researchers (4)
  • Funded Activities (38)
  • Organisations (14)
  • Funded Activity

    Improving The Clinical Management Of Obese Youth.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $217,274.00
    Summary
    Compared with normal-weight children, obese youth have a higher chance of developing diseases like Type 2 diabetes. With 1 in 4 Australian children now being overweight or obese, effective treatment programs need to be developed alongside those aimed at prevention. This program of research aims to identify which overweight/obese children are most likely to develop diabetes, with a particular focus on how infant nutrition regulates important growth factors to alter long-term diabetes risk.
    More information
    Funded Activity

    In Vitro And In Vivo Assessment Of The Funhaler -an Innovative Therapeutic Device For Children

    Funder
    National Health and Medical Research Council
    Funding Amount
    $472,750.00
    Summary
    Aerosol therapy is the most effective form of treatment for children with respiratory diseases such as asthma. While optimising aerosol delivery systems has an important role in increasing the efficacy of asthma therapy, ensuring patient compliance is often the most difficult part of the clinician's role, particularly in the paediatric age group. An innovative small volume spacer device (Funhaler) developed by a West Australian company (InfaMed, Ltd) may help overcome this problem. The Funhaler .... Aerosol therapy is the most effective form of treatment for children with respiratory diseases such as asthma. While optimising aerosol delivery systems has an important role in increasing the efficacy of asthma therapy, ensuring patient compliance is often the most difficult part of the clinician's role, particularly in the paediatric age group. An innovative small volume spacer device (Funhaler) developed by a West Australian company (InfaMed, Ltd) may help overcome this problem. The Funhaler incorporates a spinning toy attached to the outside of the spacer. The toy is activated when the patient breathes through the spacer. The device has been designed to encourage children to co-operate when their asthma therapy is being delivered. The Funhaler is currently in the late development stage. We propose, firstly, to carry out in vitro assessments of drug delivery from the Funhaler compared to the two most widely available small volume spacers: the Aerochamber Plus (Trudell, Canada) and the Breath-A-Tech (Scott-Dibben, Australia). These assessments will be carried out to meet the standards of regulatory bodies worldwide (including the FDA). Secondly, we propose to perform extensive in vivo studie: filter studies to assess drug delivery to the patient; deposition studies to measure drug deposition in the lungs; and a pilot clinical trial to assess the efficacy of the device during medium to long-term use in children aged 2-8 years.
    Read more Read less
    More information
    Funded Activity

    Growth Study In Normal Children And In Genetic Abnormal Ity 'fragile X'

    Funder
    National Health and Medical Research Council
    Funding Amount
    $571,759.00
    More information
    Funded Activity

    Contribution Of Systemic Inflammatory Response To Brain Injury In Growth Restricted Newborns

    Funder
    National Health and Medical Research Council
    Funding Amount
    $363,388.00
    Summary
    Growth restriction during pregnancy can damage the baby’s brain and result in poor outcomes such as learning and attention difficulties and cerebral palsy. Currently there is no treatment available to prevent brain injury in these babies. This study will explore the role of inflammation and brain injury in the growth restricted baby. We will also examine whether a readily available and safe anti-inflammatory treatment can reduce or prevent brain injury following growth restriction.
    More information
    Funded Activity

    Immune-regulation By Milk Extracts In Vitro As Well As In Vivo In An Animal Model Of Formula Feeding

    Funder
    National Health and Medical Research Council
    Funding Amount
    $369,500.00
    More information
    Funded Activity

    The Stunting Risk Assessment Tool: Identifying Infants At High Risk Of Impaired Growth And Development In Resource Poor Settings.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $344,644.00
    Summary
    Stunting is a neglected global health crisis. After the age of 2, irreversible health, developmental and economic consequences occur that are perpetuated across generations. Early risk prediction is key to more effective interventions. By determining the contribution of risk factors in pregnancy and early infancy, I propose to develop a tool that can be used by health workers to identify infants at high risk of stunting in early life, so that early preventive measures can be introduced.
    More information
    Funded Activity

    Trabecular Architecture During Growth - Does It Determine Metaphyseal Peak Bone Strength In Adulthood?

    Funder
    National Health and Medical Research Council
    Funding Amount
    $165,339.00
    Summary
    Skeletal fragility is common is elderly people but has its origin in childhood. Strong bone established during growth will provide more protection against occurrence of fragility fracture in old age. Identifying individuals during childhood who are at high risk of skeletal fragility, and early intervention is a strategic approach managing the burden of skeletal fragility on the ageing population.
    More information
    Funded Activity

    Neurodevelopmental Outcomes After Novel Interventions In Newborn Infants

    Funder
    National Health and Medical Research Council
    Funding Amount
    $188,226.00
    Summary
    Children who were sick in the newborn period or born preterm are at increased risk of abnormal development, particularly problems with their ability to walk, think and learn. This research will assess how new treatments affect sick newborns’ later development. For example, giving preterm babies healthy germs, or probiotics, decreases a serious bowel infection, called necrotising enterocolitis or NEC. This research will find out if they also help preterm brain development when the children are 2 .... Children who were sick in the newborn period or born preterm are at increased risk of abnormal development, particularly problems with their ability to walk, think and learn. This research will assess how new treatments affect sick newborns’ later development. For example, giving preterm babies healthy germs, or probiotics, decreases a serious bowel infection, called necrotising enterocolitis or NEC. This research will find out if they also help preterm brain development when the children are 2 years old.
    Read more Read less
    More information
    Funded Activity

    Reducing Morbidities In Preterm Growth Restricted Neonates.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $687,214.00
    Summary
    Intrauterine growth restriction (IUGR) is a serious complication of pregnancy and occurs when fetal growth is abnormal, resulting in a fetus that is smaller than it should be for its given gestational age. IUGR babies are at much greater risk of many short and long-term adverse outcomes. This study investigates the role that adverse cardiovascular development plays in the progression of lung, heart and brain disease in preterm IUGR newborns.
    More information
    Funded Activity

    Improving The Efficacy Of Retinoid Therapy In Childhood Neuroblastoma

    Funder
    National Health and Medical Research Council
    Funding Amount
    $295,336.00
    Summary
    Cancer is still the commonest disease causing death in chilhood. Childhood neuroblastoma is a cancer of the nerve tissue which presents usually as a widely spread malignancy, which responds poorly to conventional therapy, indicating the need for novel treatment approaches. Vitamin A derivatives, or retinoids, given in addition to conventional therapy improves the cure rate for children with advanced neuroblastoma to 50%. We have shown that one likely mechanism of retinoid resistance is a deficie .... Cancer is still the commonest disease causing death in chilhood. Childhood neuroblastoma is a cancer of the nerve tissue which presents usually as a widely spread malignancy, which responds poorly to conventional therapy, indicating the need for novel treatment approaches. Vitamin A derivatives, or retinoids, given in addition to conventional therapy improves the cure rate for children with advanced neuroblastoma to 50%. We have shown that one likely mechanism of retinoid resistance is a deficiency of retinoic acid receptor beta, which is a necessary factor in the neuroblastoma cell for converting the retinoid anti-cancer signal into an irreversible cellular change. In this project we will define why some neuroblastoma cells express low levels of this protein and test new retinoid therapies.
    Read more Read less
    More information

    Showing 1-10 of 38 Funded Activites

    • 1
    • 2
    • 3
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback